FDA taps chemoradio-sensitizing head and neck cancer drug as 'breakthrough'
Years after a family of endogenous proteins known as IAP, or inhibitors of apoptosis proteins, was first linked to poor prognosis of cancer, the FDA is helping move along a drug that blocks it.
Debiopharm’s Debio 1143 now enjoys breakthrough status at the agency, after Phase II results unveiled at ESMO suggested that adding it to a regimen of chemoradiation therapy boosted locoregional control rate as well as progression-free survival among patients with “high risk” locally advanced squamous cell carcinoma of the head and neck.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
